U.S. Sucralfate Industry Continues To Grow With Increasing Cases Of Duodenal And Gastric Ulcers In The U.S.
Sucralfate is a cytoprotective agent that protects cells from damage caused by gastric acid, alcohol and acetylsalicylic acid. This medication comes in tablet and suspension forms. It was approved by the FDA in 1982. It is not considered to be safe for children. While its use is generally safe, children should not take it more often than prescribed. If the medication is prescribed for more than eight weeks, the patient should consult a doctor or pharmacist. The oral solution of sucralfate is a commonly prescribed medication for the treatment of intestine ulcers. It helps heal ulcers by forming a protective coating that prevents further injury and promotes healing. It is recommended to take the medication on an empty stomach at least 1 hour before a meal. The dosage of sucralfate is based on the medical condition of the patient. This medication is not suitable for use during pregnancy.
According to the "Coherent Market Insights" Global
Industry Insights, Trends, Outlook, and Opportunity Analysis of U.S.
Sucralfate Market.
U.S. Sucralfate Market |
The U.S. sucralfate market is expected to grow in
the near future, owing to an increase in the number of people suffering from
duodenal and gastric ulcers. Furthermore, the number of patients with H. pylori
infection is rising at an accelerated rate, increasing the risk of duodenal and
gastric ulcers in the U.S. Before taking
sucralfate, consulting with a physician before taking any antacids or other
medications is important. The effects of antacids on the gastrointestinal
system may reduce the ability of sucralfate to prevent a gastrointestinal
upset. Likewise, patients undergoing enteral tube feeding should inform their
doctor if they are pregnant or are planning to become pregnant.
The U.S. sucralfate industry is expected to witness
excellent growth over the forecast period. The major factors driving the market
growth are increasing gastrointestinal disorders and H. pylori-associated
infections, and research and development activities by key players. Moreover, the number of patients with H.
pylori infection is rising at an accelerated rate, increasing the risk of
duodenal and gastric ulcers in the U.S. further expanding growth of the U.S.
sucralfate industry. Recently in December 2019, the US Food and Drug
Adiministration (FDA) granted approval to Amneal Pharmaceuticals, Inc. for its
Abbreviated New Drug Application for a generic version of sucralfate oral
suspension, 1g/10 ml.
Comments
Post a Comment